US2005164279A1PendingUtilityA1
Secreted and transmembrane polypetides and nucleic acids encoding the same
Est. expiryMar 3, 2020(expired)· nominal 20-yr term from priority
C07K 14/4703C12P 21/02G01N 33/502C12Q 1/6886C12Q 2600/158G01N 33/505G01N 33/5044C07K 2317/24C12Q 2600/136C07K 2319/00G01N 33/53C12N 2799/026Y10S530/828G01N 33/5014C12N 9/00C12P 21/06C07K 2319/30C07K 17/00G01N 33/5011C07K 14/70578C07K 1/00G01N 33/5008G01N 33/5061G01N 33/68C12N 15/00C12N 5/06G01N 2800/042G01N 33/6845C12N 9/001C07K 16/18A61K 38/00C12Q 1/68C07K 14/00Y10S530/866G01N 33/5758G01N 33/575C07K 14/82C12N 9/1051C07K 14/47C07K 14/705C07K 14/4748A61K 39/001102A61K 39/00G01N 2500/00C12N 9/90C07K 14/70546C07K 14/46A61K 39/395A61K 38/17
71
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Claims
exact text as granted — not AI-modified1 . A diagnostic method, comprising determining, in a test biological sample obtained from a mammalian subject, the level of nucleic acid encoding a PRO4314 polypeptide of SEQ ID NO:2 relative to the level of said nucleic acid in a corresponding normal biological sample wherein increased level of said nucleic acid in the test biological sample is indicative that the test biological sample contains cancerous cells.
2 . The method of claim 1 wherein the test and normal biological samples are tissue samples.
3 . The method of claim 2 wherein the test tissue sample is from lung or breast tissue.
4 . The method of claim 3 wherein the normal biological sample is from the same type of tissue as the test biological sample.
5 . The method of claim 2 wherein the normal biological sample is an epithelial tissue sample from a combination of tissues.
6 . The method of claim 5 wherein epithelial tissue sample includes epithelial cells from lung or breast tissue.
7 . The method of claim 1 wherein the nucleic acid levels are determined by hybridization of nucleic acid obtained from the test and normal biological samples to one or more probes specific for the nucleic acid encoding PRO4314.
8 . The method of claim 7 wherein hybridization is performed under stringent conditions.
9 . The method of claim 8 wherein said stringent conditions use 50% formamide, 5×SSC, 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5× Denhardt's solution, sonicated salmon sperm DNA (50 μg/ml), 0.1% SDS, and 10% dextran sulfate at 42° C., with washes at 42° C. in 0.2×SSC and 50% formamide at 55° C., followed by a wash comprising of 0.1×SSC containing EDTA at 55° C.
10 . The method of claim 7 wherein the nucleic acids obtained from the test and normal biological samples are cDNAs.
11 . The method of claim 10 wherein the nucleic acids obtained from the test and normal biological samples are placed on microarrays.
12 . A diagnostic method comprising determining the expression level of the PRO4314 polypeptide of SEQ ID NO: 2 in test biological sample relative to a normal biological sample, wherein overexpression of said polypeptide in the test biological sample is indicative that the sample contains cancerous cells.
13 . The method of claim 12 wherein the test and normal biological samples are tissue samples.
14 . The method of claim 13 wherein the test tissue sample is from lung or breast tissue.
15 . The method of claim 14 wherein overexpression is detected with an antibody that specifically binds to the PRO4314 polypeptide.
16 . The method of claim 15 wherein said antibody is a monoclonal antibody.
17 . The method of claim 16 wherein said antibody is a humanized antibody.
18 . The method of claim 17 wherein said antibody is an antibody fragment.
19 . The method of claim 18 wherein said antibody is labeled.Join the waitlist — get patent alerts
Track US2005164279A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.